SIVEXTRO FILM-COATED TABLET 200MG

PATHEON INC. (CANADA)🇸🇬 Health Sciences Authority

Approval Date: Sep 16, 2015
Approval ID: 582a4f3f3c3964d1
Company: PATHEON INC. (CANADA)
Type: Therapeutic

Approval Details

Approval Id: 582a4f3f3c3964d1
Drug Name: SIVEXTRO FILM-COATED TABLET 200MG
Product Name: SIVEXTRO FILM-COATED TABLET 200MG
Approval Number: SIN14850P
Approval Date: 2015-09-16
Registrant: MSD PHARMA (SINGAPORE) PTE. LTD.
Licence Holder: MSD PHARMA (SINGAPORE) PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage The recommended dosage of SIVEXTRO is 200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 18 years of age or older. The recommended dosage and administration is described in Table 1. <img src="/TGIF/Sivextro-Table1.png" alt="Sivextro Dosage Table 1" /> No dose adjustment is necessary when changing from intravenous to oral SIVEXTRO. If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose. 2.2 Preparation and Administration of Intravenous Solution SIVEXTRO is supplied as a sterile, lyophilized powder for injection in single-use vials of 200 mg. Each 200 mg vial must be reconstituted with Sterile Water for Injection and subsequently diluted only with 0.9% Sodium Chloride Injection, USP. SIVEXTRO vials contain no antimicrobial preservatives and are intended for single use only. Preparation The contents of the vial should be reconstituted using aseptic technique as follows: Note: To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after reconstitution. <ol> <li>Reconstitute the SIVEXTRO vial with 4 mL of Sterile Water for Injection.</li> <li>Gently swirl the contents and let the vial stand until the cake has completely dissolved and any foam disperses.</li> <li>Inspect the vial to ensure the solution contains no particulate matter and no cake or powder remains attached to the sides of the vial. If necessary, invert the vial to dissolve any remaining powder and swirl gently to prevent foaming. The reconstituted solution is clear and colorless to pale-yellow in color; the total storage time should not exceed 24 hours at either room temperature (23°C – 25°C) or under refrigeration at 2°C to 8°C (36°F to 46°F).</li> <li>Tilt the upright vial and insert a syringe with appropriately sized needle into the bottom corner of the vial and remove 4 mL of the reconstituted solution. Do not invert the vial during extraction.</li> <li>The reconstituted solution must be further diluted in 250 mL of 0.9% Sodium Chloride Injection, USP. Slowly inject the 4 mL of reconstituted solution into a 250 mL bag of 0.9% Sodium Chloride Injection, USP. Invert the bag gently to mix. Do NOT shake the bag as this may cause foaming.</li> </ol> Administration Administer as an intravenous infusion only. Do not administer as an intravenous push or bolus. Do not mix SIVEXTRO with other drugs when administering. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration. The intravenous bag containing the reconstituted and diluted intravenous solution should be inspected visually for particulate matter prior to administration. Discard if visible particles are observed. The resulting solution is clear and colorless to pale-yellow in color. After reconstitution and dilution, SIVEXTRO is to be administered via intravenous infusion using a total time of 1 hour. The total time from reconstitution to administration should not exceed 24 hours at room temperature (23°C – 25°C) or under refrigeration at 2°C to 8°C (36°F to 46°F). 2.3 Compatible Intravenous Solutions SIVEXTRO is compatible with 0.9% Sodium Chloride Injection, USP. 2.4 Incompatibilities SIVEXTRO for injection is incompatible with any solution containing divalent cations (e.g., Ca2+, Mg2+), including Lactated Ringer’s Injection and Hartmann’s Solution. Limited data are available on the compatibility of SIVEXTRO for injection with other intravenous substances, additives or other medications and they should not be added to SIVEXTRO single-use vials or infused simultaneously. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of SIVEXTRO with 0.9% Sodium Chloride Injection, USP.
Route Of Administration: ORAL
Indication Info: 1 INDICATIONS AND USAGE 1.1 Acute Bacterial Skin and Skin Structure Infections SIVEXTRO is an oxazolidinone-class antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications: 4 CONTRAINDICATIONS SIVEXTRO is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients in the drug product.
Atc Code: J01XX11
Atc Item Name: tedizolid
Pharma Manufacturer Name: MSD PHARMA (SINGAPORE) PTE. LTD.
Company Detail Path: /organization/msd-pharma-singapore-pte-ltd

Active Ingredients

Tedizolid 165mg eqv Tedizolid phosphate

200mg

TEDIZOLID 165 MG EQV TEDIZOLID PHOSPHATE

200 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Sep 16, 2015

Approval ID

582a4f3f3c3964d1

Type

Therapeutic

Back to HSA Approvals